Abstracts tagged "Biomarkers"

Abstract Number: 1992 • 2015 ACR/ARHP Annual Meeting
Plasma Endothelin-1 Parallels the Vasoconstriction Phase in Reversible Cerebral Vasoconstriction Syndrome
Seby John¹, Leonard H. Calabrese², Juan J. Maya³, Alex Massiello⁴, Ken Uchino¹, Serpil Erzurum⁵, Allison Janocha⁵ and Rula A Hajj-Ali⁶, ¹Cerebrovascular Center, Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ³Internal Medicine, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Cleveland Clinic, Cleveland, OH, ⁶Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Plasma Endothelin-1 parallels the vasoconstriction phase in Reversible Cerebral Vasoconstriction SyndromeBackground/Purpose: Cerebral vasoconstriction is thought to be the underlying pathogenetic mechanism of Reversible Cerebral Vasoconstriction…
Abstract Number: 2611 • 2015 ACR/ARHP Annual Meeting
Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)
Keisuke Izumi¹, Misato Hashizume², Yuko Kaneko³, Keiko Yoshimoto¹ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Product Research Department, Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose : Interstitial pneumonia (IP) is one of the most critical complications in rheumatoid arthritis (RA). Severe IP is developed in zymosan-treated SKG mice, and…
Abstract Number: 3034 • 2015 ACR/ARHP Annual Meeting
A Comparative Metabolomic Evaluation of Behcet’s Disease with Arthritis and Seronegative Arthritis Using Synovial Fluid
Joong Kyong Ahn¹, Sooah Kim², Jungyeon Kim², Jiwon Hwang³, Hyungjin Kim⁴, Hyemin Jeong⁵, Yeong Hee Eun⁶, Chan Hong Jeon⁷, Jaejoon Lee⁵, Eun-Mi Koh⁵, Kyoung Heon Kim² and Hoon-Suk Cha⁸, ¹Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Biotechnology, Korea University Graduate School, Seoul, South Korea, ³Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁷Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Behcet’s disease (BD) is a chronic, complex systemic vasculitis of unknown etiology characterized by orogenital ulcers, uveitis, and arthritis. Arthritis and arthralgias in BD…
Abstract Number: 292 • 2015 ACR/ARHP Annual Meeting
Neoepitope Biomarkers As Biomarkers of Polymyositis and Dermatomyositis and Functional Status
Anders Nedergaard¹, Kim Henriksen², Morten Asser Karsdal³, Wendy White⁴ and Xiang Guo⁴, ¹Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, Copenhagen NW, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are inflammatory conditions characterized by persistent inflammation of muscle tissue (and for DM also skin). Myositis has been shown…
Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Jose Inciarte-Mundo¹, Julio Ramírez¹, Virginia Ruiz-Esquide¹, M. Victoria Hernández¹, Oscar Camacho¹, Sonia Cabrera-Villalba¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ²Immunology Department, Hospital Clinic i Provincial, Barcelona, Spain
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…
Abstract Number: 1105 • 2015 ACR/ARHP Annual Meeting
The IgG/IgG4 mRNA Ratio By Quantitative PCR Accurately Diagnoses IgG4-Related Disease and Predicts Treatment Response
Lowiek Hubers¹, Marieke Doorenspleet², Paulus Klarenbeek³, Emma Culver⁴, Lucas Maillette de Buy Wenniger⁵, Roger Chapman⁴, Stan Van de Graaf⁶, Joanne Verheij⁷, Thomas Van Gulik⁸, Frank Baas⁹, Ellie Barnes⁴, Ulrich Beuers¹ and Niek De Vries³, ¹Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Translational Gastroenterology Unit and NDM Oxford University, Translational Gastroenterology Unit and NDM Oxford University, John Radcliffe Hospital/Oxford University, Oxford, United Kingdom, ⁵1Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research,, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Dept. of Pathology, Dept. of Pathology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁸Dept. of Surgery, Dept. of Surgery, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁹Dept. of Genome Analysis, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose : IgG4-associated cholangitis (IAC) and autoimmune pancreatitis (AIP) are major manifestations of IgG4-related disease (IRD). Misdiagnosis and inadequate treatment are common since IAC and…
Abstract Number: 1667 • 2015 ACR/ARHP Annual Meeting
Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Canestri, Clara Di Mario, Marcin Nowik and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for Rheumatoid Arthritis (RA) and it is a modifier of B cell subsets in vivo, inducing changes in…
Abstract Number: 2019 • 2015 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammatory Arthritis in First Degree Relatives of Patients with Rheumatoid Arthritis and Their Association with Lifestyle Risk Factors
Jamie C Sergeant and RA-MAP Consortium, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP) and C-reactive protein (CRP) are known serum biomarkers of inflammatory arthritis (IA) and have potential predictive…
Abstract Number: 2612 • 2015 ACR/ARHP Annual Meeting
Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: A number of composite outcome measures have been validated to quantify disease activity in Rheumatoid Arthritis (RA). Few studies have been published on the…
Abstract Number: 3083 • 2015 ACR/ARHP Annual Meeting
Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus
Tianfu Wu¹, Huihua Ding², Cristina Arriens³, Chungwen Wei⁴, Jennifer H. Anolik⁵, David R. Karp³, Nancy J. Olsen⁶, Michelle Petri⁷, Ignacio Sanz⁴, Ramesh Saxena⁸ and Chandra Mohan², ¹Department of Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering, University of Houston, Houston, TX, ³Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Rheumatology, Emory University, Atlanta, GA, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁸Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Given that early detection of renal involvement in systemic lupus erythematosus (SLE) and prompt management of the disease can have a significant impact on…
Abstract Number: 303 • 2015 ACR/ARHP Annual Meeting
Mining RNA-Seq of Peripheral Blood Mononuclear Cells from JDM Alone Compared with JDM Plus Psoriasis for Biomarkers of Disease Activity
Elisha D.O. Roberson¹, Li Cao², Gabrielle A. Morgan^3,4,5, Adam Ostrower^3,4,5, Chiang-Ching Huang⁶ and Lauren M. Pachman^3,4,5, ¹John T. Milliken Department of Medicine, Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²John T. Milliken Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁴Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL, ⁶Zilber School of Public Health, University of Wisconsin, Milwaukee, Milwaukee, WI
Background/Purpose: Our CureJM JDM Registry/Repository contains sequential samples of peripheral blood mononuclear cells (PBMCs) and sera obtained every 6 months from over 467 children with…
Abstract Number: 633 • 2015 ACR/ARHP Annual Meeting
Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹, Leah Medrano² and Mara McAdams-Demarco³, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Anti-centromere antibodies (ACA) define a subgroup of Sjögren’s syndrome (SS) patients who are often older, have more frequent Raynaud’s phenomenon, and a lower frequency…
Abstract Number: 1149 • 2015 ACR/ARHP Annual Meeting
The Active Metabolite of Fostamatinib, R406, Only Decreases the Inflammation-Driven Extracellular Matrix Turnover of the Joint at High Concentrations Ex Vivo
Cecilie F. Kjelgaard-Petersen^1,2, Christian S. Thudium¹, Anne Sofie Siebuhr¹, Thorbjørn G. Christiansen³, Morten Asser Karsdal¹, Per Hägglund² and Anne C. Bay-Jensen⁴, ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark, ³Gentofte University Hospital, Orthopaedicsurgery unit, Gentofte, Denmark, ⁴Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis are degenerative diseases of the whole joint. The extracellular matrix (ECM) turnover is highly regulated in response to the…
Abstract Number: 1679 • 2015 ACR/ARHP Annual Meeting
Vicm Is a Novel Biomarker of Macrophage Activity Evaluated in a Phase IIb Clinical Trial of Mavrilimumab
Anne C. Bay-Jensen¹, Xiang Guo², Joachim Høg Mortensen¹, Morten Asser Karsdal¹ and Wendy White², ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease driven by chronic inflammation, upheld by sustained recruitment and infiltration of leucocytes, especially macrophages. Mavrilimumab is a…
Abstract Number: 2032 • 2015 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis
Olga S. Zhukov¹, Rania W. Abolhosn¹, Jonnielyn G. Rivera¹, Mary Lape Nixon², Robert J. Lagier³, Harry E. Prince⁴, Hollis J. Batterman⁴ and Stanley J. Naides¹, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Lab Sciences, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Lab Services, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA
Background/Purpose: Chikungunya fever virus (CHIK) is emerging in the western hemisphere as a mosquito-borne, acute onset arthritis. The majority of cases progress to persistent moderate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.